A multistep procedure for the chemical inactivation of human immunodeficiency virus for use as an experimental vaccine.
The kinetics of inactivation of four different strains of HIV-1 (RF, MN, SF2 and IIIB) by beta-propiolactone (BPL) and binary ethylenimine (BEI) were studied under various conditions. The conditions that would be required for the reduction of virus infectivity by at least 10(20) TCID50 ml-1 were estimated on the basis of the experimental rates of inactivation obtained. A multiple step procedure including treatment with 0.2% BPL, 0.05% sodium cholate, 10 mM BEI and 0.02% formaldehyde was designed to inactivate HIV-1 for use as an experimental vaccine. Complete inactivation of virus infectivity was confirmed by prolonged cell culture. The experimental vaccine preparation was analysed for the presence of HIV-1 proviral DNA utilizing the polymerase chain reaction. After treatment with both BPL and BEI proviral DNA was detected in one of four samples using primers encoding a 244 bp segment of the pol region of the viral genome. Proviral DNA could not be detected in any of the four samples using primers encoding segments of > 400 bp in the gag and reverse transcriptase region.
Race
E
E
Department of Academic Virology, London Hospital Medical College, UK.
Stein
C A
CA
Wigg
M D
MD
Baksh
A
A
Addawe
M
M
Frezza
P
P
Oxford
J S
JS
D016915:AIDS Vaccines / Q000494:pharmacology*; D001388:Aziridines / Q000494:pharmacology*; D004279:DNA, Viral / Q000187:drug effects; D004797:Enzyme-Linked Immunosorbent Assay; D015488:HIV Antigens / Q000032:analysis / Q000276:immunology; D016655:HIV Core Protein p24 / Q000032:analysis / Q000276:immunology; D015699:HIV Envelope Protein gp120 / Q000032:analysis / Q000276:immunology / Q000494:pharmacology; D015497:HIV-1 / Q000187:drug effects* / Q000254:growth & development / Q000276:immunology*; D006801:Humans; D011420:Propiolactone / Q000494:pharmacology*; D015164:Vaccines, Inactivated / Q000494:pharmacology
D016915:AIDS Vaccines; D001388:Aziridines; D004279:DNA, Viral; D015488:HIV Antigens; D016655:HIV Core Protein p24; D015699:HIV Envelope Protein gp120; D015164:Vaccines, Inactivated; C033132:aziridine; D011420:Propiolactone